Effects of Fenofibric Acid on Diabetic Macular Edema: The MacuFen study

References

• Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010;376(9739):124–136
   Google Scholar
• Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema; ETDRS report number 1. Arch Ophthalmol 1985;103(12):1796–1806
   PubMedGoogle Scholar
• Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep 2012;12(4):346–354
   PubMed Web of Science ®Google Scholar
• Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study). A 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010;33(2):2399–2405
   Google Scholar
• Bandello F, Cunha-Vaz J, Chong NV, et al. New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel. Eye (Lond) 2012;26(4):485–493
   Google Scholar
• The PKC-DMES Study group. Effect of ruboxistaurin in patients with diabetic macular edema. Arch Ophthalmol 2007;125(3):318–324
   Google Scholar
• Aiello LP, Vignati L, Sheetz MJ, et al. for the PKC-DRS and PKC-DRS2 Study Groups. Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2. Retina 2011;31(10):2084–2094
   PubMed Web of Science ®Google Scholar
• Simo R, Hernandez C. Advances in the medical treatment of diabetic retinopathy. Diabetes Care 2009;32(8):1556–1562
   PubMed Web of Science ®Google Scholar
• Javey G, Schwartz SG, Flynn HW Jr. Emerging pharmacotherapies for diabetic macular edema. Exp Diabetes Res 2012;2012:548732 . doi: 10.1155/2012/548732
   PubMedGoogle Scholar
• Keech AC, Mitchell P, Summanen PA, et al., for the FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. Lancet 2007;370(9600):1687–1697
   PubMed Web of Science ®Google Scholar
• The ACCORD study group and ACCORD Eye study group. Effects of medical therapies on retinopathy progresion in type 2 diabetes. N Engl J Med 2010;363(3):233–244
   PubMed Web of Science ®Google Scholar
• Ansquer JC, Crimet D, Foucher C. Fibrates and statins in the treatment of diabetic retinopathy. Curr Pharm Biotechnol 2011;12(3):396–405
   PubMed Web of Science ®Google Scholar
• Villarroel M, Garcia-Ramirez M, Corraliza L, et al. Fenofibrate prevents retinal pigment epithelium disruption induced by interleukin-1β by suppressing AMP-activated protein kinase (AMPK) activation. Diabetologia 2011;54(6):1543–1553
   Google Scholar
• Simó R, Roy S, Béhar-Cohen F, et al. Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives. Curr Med Chem 2013;20(26):3258–3266
   PubMed Web of Science ®Google Scholar
• Massin P, Vicaut E, Haouchine B, et al. Reproducibility of retinal mapping using optical coherence tomography. Arch Ophthalmol 2001;119(8):1135–1142
   Google Scholar
• Chan A, Duker JS, Ko TH, et al. Normal macular thickness measurements in healthy eyes using stratus optical coherence tomography. Arch Ophthalmol 2006;124(2):193–198
   PubMedGoogle Scholar
• Diabetic Retinopathy Clinical Research Network. Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. Ophthalmology 2007;114(8):1520–1525
   PubMed Web of Science ®Google Scholar
• Soomro H, Burnett L, Davies N. Quantifying changes in retinal anatomy after interventions for diabetic maculopathy. Br J Diabetes Vasc Dis 2007;7(4):181–185
   Google Scholar
• Scott IU. Edwards AR, Beck RW, et al. Diabetic Retinopathy Clinical Research Network. A phase 2 randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114(10):1860–1867
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2010;117(11):2146–2151
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117(6):1064–1077
   PubMed Web of Science ®Google Scholar
• Sander B, Thornit DL, Colmorn L, et al. Progression of diabetic macular edema: correlation with blood-retinal barrier permeability, retinal thickness, and retinal vessel diameter. Invest Ophthalmol Vis Sci 2007;48(9):3983–3987
   Web of Science ®Google Scholar
• Cukras CA, Petrou P, Chew EY, et al. Oral minocycline for the treatment of diabetic macular edema (DME): results of a phase I/II clinical study. Invest Ophthalmol Vis Sci 2012;53(7):3865–3874
   PubMed Web of Science ®Google Scholar
• Beck RW, Moke PS, Turpin AH, et al. A computerized method of VA testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol 2003;135(2):194–205
   Web of Science ®Google Scholar
• Writing committee for the Diabetic Retinopathy Clinical Research Network. Comparison of the modified early treatment diabetic retinopathy study and mild macular edema grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol 2007;125(4):469–480
   PubMedGoogle Scholar
• Stewart MW. Critical appraisal of ranibizumab in the treatment of diabetic macular edema. Clin Ophthalmol 2013;7:1257–1267
   Google Scholar
• Lang GE, Berta A, Eldem BM, et al. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE Extension Study. Ophthalmology 2013;120(10):2004--2012
   Google Scholar
• Brown DM, Nguyen QD, Marcus DM, et al. for the RIDE and RISE Research Group. The 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013;120(10):2013--2022
   Google Scholar
• The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 2005;366(9500):1849–1861
   PubMed Web of Science ®Google Scholar